MASLD aspirin may help decrease liver fat
a recent article found that aspirin reduced the severity of metabolic dysfunction-associated steatotic liver disease (MASLD): NAFLD aspirin dec liver fat JAMA2024 in dropbox, or doi:10.1001/jama.2024.1215. The commentary section below details the new nomenclatures for steatotic liver diseases, per the AASLD (the American Association for the Study of Liver Diseases) Details : -- 80 participants 18 to 70 years old who had established MASLD were enrolled in a six-month phase-2 randomized double-blind placebo-controlled clinical trial -- patients were excluded if they had other causes of hepatic steatosis, including significant alcohol intake (at least three drinks per day for men or two drinks a day for women), diagnosis of viral hepatitis, hemochromatosis, alpha-1 anti-trypsin deficiency, Wilson’s disease, autoimmune hepatitis, or HIV -- patients were randomized to aspirin 81 mg versus matching placebo, along with standard nutritional couns...